Trial
NCT06336434
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
—
Condition
HIV-1-infection
Intervention
CAB LA 600mg
Why stopped
Due to shifting priorities and reduced funding, the IMPAACT Network is not able to continue efforts toward opening IMPAACT 2040.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-31